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PCLINICAL RESEARCH Pharmacologic Studies
Long-Term Safety of a Novel Antianginal
Agent in Patients With Severe Chronic Stable Angina
The Ranolazine Open Label Experience (ROLE)
Michael J. Koren, MD, FACC,* Michael R. Crager, PHD,† Michael Sweeney, MD†
Jacksonville, Florida
Objectives This report describes safety and tolerability data from 746 chronic angina patients treated in the ROLE (Ranola-
zine Open Label Experience) program.
Background Ranolazine treats angina without depressing hemodynamic status. The long-term safety and tolerability of rano-
lazine have not been previously reported.
Methods Patients with severe functional impairment from angina (mean Duke Treadmill Score [DTS] of 14.4) who com-
pleted 1 of 2 randomized treadmill trials entered the ROLE program. Ranolazine was titrated to optimal dosages
between 500 and 1,000 mg twice daily. Physical examination, laboratory tests, and adverse event reporting
were performed periodically. We conducted analyses to evaluate possible predictors of ranolazine intolerance,
such as advanced age, diabetes, poor exercise tolerance, or history of myocardial infarctions or congestive heart
failure (CHF). The ROLE program’s mortality was compared against the DTS predictive model and other contem-
porary cohorts of high-risk CHD patients.
Results Mean follow-up was 2.82 years. Two years after initial dosing, 571 patients (76.7%) remained on therapy and
72 patients (9.7%) discontinued ranolazine due to adverse events. Among 6 factors evaluated, only age 64
years predicted for higher withdrawal rates. Patients with a history of CHF had lower withdrawal rates. Mean QTc
interval was prolonged by 2.4 ms. No treatment discontinuations occurred due to QTc prolongation, and no Tor-
sades de Pointes was reported. Sixty-four deaths occurred during a total of 2,102 patient-years (3.0% annually)
during the ROLE program. When extending observations to all patients exposed to ranolazine during the double-
blind trials (n  972) preceding the ROLE program, annual mortality was 2.8% compared with 5% as pre-
dicted by DTS.
Conclusions Long-term therapy with ranolazine seems well tolerated in high-risk CHD patients. Survival analyses suggest that
symptomatic improvements attributable to ranolazine are not offset by increased mortality. (J Am Coll Cardiol
2007;49:1027–34) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.067w
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Canolazine is a novel antianginal agent. Although its
echanism of action has not been fully elucidated, ranola-
ine seems to inhibit the late sodium current in the cardiac
yocyte, reducing calcium and sodium overload and thereby
ncreasing the efficiency of oxygen use. Its therapeutic effects
o not depend on reductions in heart rate, blood pressure, or
ascular resistance (1– 4) Three multicenter placebo-
ontrolled trials of extended-release (SR) ranolazine have
emonstrated angina symptom improvements as assessed
ither by treadmill performance or patient diaries (1,2,5).
The MARISA (Monotherapy Assessment of Ranolazine
n Stable Angina) trial (1) was a 4-group crossover study in
rom the *Jacksonville Center for Clinical Research, Jacksonville, Florida; and †CV
herapeutics, Inc., Palo Alto, California. This work was supported by CV Thera-
eutics, Inc.l
Manuscript received August 14, 2006; revised manuscript received October 26,
006, accepted October 30, 2006.hich 191 patients received ranolazine SR at dosages of
00, 1,000, and 1,500 mg twice daily (b.i.d.) and placebo in
andomly ordered 1-week phases. All active treatment dosages
ere associated with improvements in total and angina-free
readmill exercise duration. The CARISA (Combination As-
essment of Ranolazine in Stable Angina) trial (2) was a
2-week, 3-group parallel study of 823 patients (receiving
ackground therapy with once-daily diltiazem 180 mg, ateno-
ol 50 mg, or amlodipine 5 mg) randomly assigned to receive
anolazine SR 750 or 1,000 mg b.i.d. or placebo. Both
anolazine dosages improved total and angina-free treadmill
xercise duration and reduced angina frequency and nitroglyc-
rin consumption.
The ROLE (Ranolazine Open Label Experience) pro-
ram involved patients who completed the MARISA or
ARISA trial and were willing to participate in an open-abel extension program. Because of the entry requirements
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Safety of Long-Term Ranolazine March 13, 2007:1027–34of the treadmill studies, all
ROLE program participants
were well characterized as having
severe functional limitations due
to angina and were assigned a
Duke Treadmill Score (DTS).
The DTS (6), a widely accepted
prognostic scoring system, pro-
vides a measurement by which
outcomes for the ROLE pro-
gram participants can be com-
pared with expected survival
rates. Although the open-label
methodology of the ROLE pro-
gram is unsuitable for strictly at-
tributing safety and efficacy out-
comes to ranolazine, our analysis
s intended to help clinicians identify factors more or less
ikely related to drug intolerance. In addition, the ROLE
ohort is large enough to benchmark outcomes against other
imilar groups of patients reported in published medical
eports.
ethods
tudy design. Institutional review board approval and in-
ormed consent were obtained for all patients. Upon suc-
essful completion of the MARISA or CARISA trials,
OLE program subjects were enrolled at 123 outpatient
nvestigative sites in 12 nations: Australia (1%), Canada
16%), Czech Republic (22%), Georgia (3%), Greece
1%), Israel (4%), New Zealand (2%), Poland (11%),
ussia (21%), Spain (2%), United Kingdom (1%), and the
.S. (17%). Investigators could titrate to optimal ranolazine
osages between 500 and 1,000 mg b.i.d. on the basis of
linical responses at up to 6 initial weekly visits.
aintenance-phase visits were scheduled 1 month after
ompletion of titration and every 3 months thereafter.
atients who experienced recurrent angina or adverse events
AEs) during the maintenance phase could be titrated to
igher or lower drug doses.
For MARISA patients, ranolazine was initiated at 750
g b.i.d. and increased to a maximum dose of 1,000 mg
.i.d. as guided by clinical effects. The optional addition of
ther antianginal agents was permitted. For CARISA
atients, ranolazine titration was initiated at 500 mg b.i.d.
nd could be increased to 1,000 mg b.i.d. Background
ntianginal therapy was maintained through the period of
anolazine titration, with the options of increasing or
ecreasing the dose, substituting another background anti-
nginal agent, or discontinuing background antianginal
herapy left to investigators. Open-label ranolazine was not
mmediately available for some of the patients who entered
he ROLE program from the CARISA trial. Among 406
Abbreviations
and Acronyms
AE  adverse event
CHD  coronary heart
disease
CHF  congestive heart
failure
DTS  Duke Treadmill
Score
ECG  electrocardiogram/
electrocardiographic
EECP  enhanced external
counterpulsation
MI  myocardial infarction
SR  extended-releaseatients who entered the ROLE program after receiving Canolazine in the CARISA trial, the resulting interruption
n ranolazine dosing averaged 4 months.
utcome measures. Safety and tolerability assessments
ncluded vital signs, electrocardiograms (ECGs), and AE
valuations. Physical examination and laboratory analyses
hematology, chemistry, and plasma ranolazine concentra-
ions) were conducted at baseline and all maintenance-phase
isits. Urinalysis and serum lipids were assessed at baseline
nd every 6 months during maintenance. Reasons for study
rug discontinuation were recorded.
tatistical analyses. Adverse events, study drug discon-
inuations, and ECG intervals were summarized, beginning
ith first exposure to open-label ranolazine and continuing
hrough April 1, 2005. Exploratory analyses were conducted
ith Cox proportional hazards regression to assess whether
ge, gender, history of myocardial infarction (MI), history
f congestive heart failure (CHF), diabetes mellitus, or
aseline exercise tolerance predicted discontinuation of
herapy due to AEs. The ECG intervals were averaged
ithin patients over the follow-up period and compared
ith pretreatment baseline with the paired Student t test.
To avoid selection biases, analyses of survival incorpo-
ated all available follow-up of patients who were exposed to
anolazine in the MARISA or CARISA trials or the ROLE
rogram, including patients who participated only in the
andomized studies. Survival time was assessed, beginning with
rst exposure to ranolazine. The ROLE program did not
equire ongoing follow-up for survival beyond 14 days after
reatment discontinuation. When patient deaths more than 14
ays after discontinuation were nonetheless reported, they were
ncluded in the analysis. Mortality per patient-year was esti-
ated assuming a constant hazard rate, and expected survival
ates at 1 and 2 years were computed. Survival over the entire
ollow-up period was described with Kaplan-Meier methods.
omparator studies. We searched the PubMed database
ith the following combination of medical subject heading
erms: “coronary disease” OR “myocardial ischemia” OR
angina pectoris” AND “prospective studies” OR “survival
emographic and Clinicalharacteristics at Baseline (n  746)
Table 1 Demographic and ClinicalCharacteristics at Baseline (n  746)
Characteristic n (%)
Men 580 (77.7)
White 722 (96.8)
Age 65 yrs 388 (52.0)
Hypertension 476 (63.8)
Previous MI 429 (57.5)
Previous revascularization 257 (34.5)
CHF 215 (28.8)
Unstable angina 172 (23.1)
Diabetes 170 (22.8)
Ventricular arrhythmias 75 (10.1)
Valvular heart disease 47 (6.3)
Stroke 35 (4.7)
Cardiac arrest 14 (1.9)HF  congestive heart failure; MI  myocardial infarction.
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March 13, 2007:1027–34 Safety of Long-Term Ranolazinenalysis” OR “treatment outcome.” PubMed search limits
ere “middle aged: 45 to 64 years,” “aged: 65 years,”
English,” “publication date from 1996 to 2005,” “clinical
rial,” and “core clinical journals.” We limited comparator
tudies to those of at least 2 years’ duration and 500 patients
xcept for one that represented the largest published expe-
ience with surgical transmyocardial laser revascularization.
esults
total of 746 patients entered the ROLE program (143 of
he 168 patients who completed the MARISA trial plus 603
f the 731 patients who completed the CARISA trial).
atient characteristics are summarized in Table 1, and the
Figure 1 The ROLE Program Schematic
Disposition of subjects in preceding double-blind trials leading to the ROLE (Ranol
CARISA  Assessment of Ranolazine in Stable Angina trial; MARISA  Monothera
Patient Disposition by Time on Open-Label Treat
Table 2 Patient Disposition by Time on Ope
Time on Open-Label Treatment
Patients with at least this much time on treatment
Patients terminating participation 11
Unacceptable adverse event 5
Elective withdrawal 3
Death 2
Patients who completed 2 yrs of ranolazine therapy*Two patients had not yet reached 2 years on open-label treatment at the ti
participation in the ROLE (Ranolazine Open Label Experience) program.ow of patients through the studies is presented in Figure 1.
he population was largely male and white. Average expo-
ure time to ranolazine was 2.82 years (range 6 days to 6.5
ears). Twenty-three percent of the population was diabetic,
nd 58% had a previous MI. Four hundred thirty-two (58%)
ubjects were titrated at some point to the highest ranola-
ine dose of 1,000 mg b.i.d., 209 subjects (28%) received a
aximum dose of 750 mg b.i.d., and 14% received 500 mg
.i.d.
iscontinuations. Patient disposition over time is shown
n Table 2. Of the original 746 patients enrolled, all but 2
ave follow-up data through 2 years or discontinued prior to
hat point owing to adverse effects, death, or choice. Five
undred seventy-one patients (76.7%) completed 2 years of
pen Label Experience) program. AE  adverse event;
essment of Ranolazine In Stable Angina trial; pts  patients.
el Treatment
2 Yrs
All Follow-Up to Date
(Mean 2.8 yrs, Max 6.5 yrs)
744*
.4%) 173 (23.3%) 290 (38.9%)
%) 72 (9.7%) 94 (12.6%)
%) 46 (6.2%) 95 (12.7%)
%) 36 (4.8%) 56 (7.5%)†
571 (76.7%)azine O
py Assment
n-Lab
1 Yr
746
5 (15
3 (7.1
1 (4.2
5 (3.4me of this analysis. †Eight additional patients died after terminating
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Safety of Long-Term Ranolazine March 13, 2007:1027–34pen-label ranolazine therapy, and 173 patients (23.3%) had
iscontinued therapy. Adverse events were the most com-
on reason for discontinuation in the first 2 years of
pen-label treatment, accounting for slightly less than
ne-half of all discontinuations (n  72 [9.7% of total
ohort]). The next most common reasons for discontinua-
ion were elective withdrawal at the discretion of patients
nd/or investigators (n  46 [6.0%]) and death (n  34
4.6%]). Adverse events are summarized by preferred term
n the MedDRA dictionary (Version 8) in Table 3. Aside
ummary of All Adverse Events >4%ncidence Reported During the ROLE Program
Table 3 Summary of All Adverse Events >4%Incidence Reported During the ROLE Program
Preferred Term
Number of Patients (%)
(n  746)
Angina pectoris 111 (14.9)
Dizziness 88 (11.8)
Constipation 81 (10.9)
Peripheral edema 62 (8.3)
Angina, unstable 53 (7.1)
Fatigue 52 (7.0)
Hypertension 48 (6.4)
Cough 45 (6.0)
Chest pain 44 (5.9)
Nausea 42 (5.6)
Headache 41 (5.5)
Myocardial infarction 37 (5.0)
Diabetes mellitus 37 (5.0)
Back pain 36 (4.8)
Anemia 34 (4.6)
Arthralgia 33 (4.4)
Asthenia 33 (4.4)
Dyspnea 32 (4.3)
Vertigo 32 (4.3)
Influenza 31 (4.2)
Acute MI 28 (3.8)
Diarrhea 28 (3.8)
I  myocardial infarction; ROLE  Ranolazine Open Label Experience.
Influence of Demographic and ClinicalCategorical Variables on Risk of D scontinuation
Table 4 Influence of Demographic and ClinicCategorical Variables on Risk of Dis
Predictor
Bre
Group 1
Group 2
746
Patients
Gender Men 580
Women 166
Age 64 yrs 389
64 yrs 357
History of MI Present 429
Absent 317
History of CHF Present 215
Absent 531
History of diabetes Present 170
Absent 576
Baseline exercise duration Median 373
Median 373*Cox proportional hazards regression analysis relative risk estimate is expres
AE  adverse event; DC  discontinuation; other abbreviations as in Tablerom angina, the symptom under study, the most common
Es recorded were dizziness (11.8%) and constipation
10.9%). These complaints, solely or in combination with
ther AEs, led to discontinuation in 7 (0.9%) and 5 (0.6%)
atients, respectively. Adverse event profiles did not differ
etween the 197 subjects who received ranolazine for the
rst time in the ROLE program (randomized to placebo in
ARISA or CARISA trials) and 549 patients who had
reviously received ranolazine.
Table 4 shows the results of predictive modeling to
nalyze possible correlations between baseline demographic
nd clinical variables and the likelihood of AE-related
iscontinuation. Older age (64 years) was the only factor
hat showed a statistically significant correlation with in-
reased AE-related discontinuation (relative risk 2.32, p 
.001). History of CHF was the only factor that showed a
ignificant correlation with reduced AE-related discontinu-
tion (relative risk 0.55, p  0.030). There was a trend
oward decreased risk of AE-related discontinuations
mong patients with a history of MI (relative risk 0.74,
 0.14) and those with baseline exercise duration shorter
han the median (relative risk 0.75, p  0.16).
CG findings. Durations of the PR, QRS, and QTc
Fridericia correction) intervals at baseline and the within-
atient average values during open-label ranolazine treat-
ent are presented in Table 5. There were no significant
hanges from baseline in either the PR or QRS interval. The
Tc interval showed a mean prolongation of approximately
.4 ms compared with baseline (p  0.001). Sixteen ECG
racings showed QTc interval prolongation exceeding 500 ms
ccurring in 10 patients (1.2%). Ten occurrences of QTc
ntervals 500 ms were recorded while patients received the
,000 mg b.i.d. dosage, and 6 occurrences were recorded at
he 750 mg b.i.d. dosage. No subject was withdrawn from the
OLE program for QTc interval prolongation. Serum elec-
rolyte levels obtained proximate to the time of QTc interval
e to AEs
inuations Due to AEs
n
Relative Risk*
(95% Confidence Interval) p Value
94 DCs
ue to AEs
72 0.931 (0.577–1.501) 0.77
22
66 2.32 (1.49–3.61) 0.001
28
47 0.74 (0.492–1.104) 0.14
47
16 0.55 (0.320–0.943) 0.030
78
22 1.04 (0.65–1.68) 0.87
72
42 0.745 (0.50–1.12) 0.16
52s Du
al
cont
akdow
Dsed as the ratio of group 1 to group 2.
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March 13, 2007:1027–34 Safety of Long-Term Ranolazinerolongation did not indicate any significant abnormalities. No
ase of Torsades de Pointes was reported.
ortality. Data were available and analyzed from a total of
,372 patient-years of follow-up of the 942 patients exposed
o ranolazine through randomization in the MARISA or
ARISA trials or in the ROLE program, incorporating
,233 patient-years of ranolazine treatment exposure. The
ifference between the patient-years of follow-up and
atient-years of treatment is due primarily to the delay in
vailability of the ROLE program for some CARISA trial
atients. There were 4 deaths during ranolazine treatment
n the MARISA and CARISA trials (vs. 3 deaths during
lacebo treatment) and 64 deaths during 2,102 patient-years
n the ROLE program (3.0% annual incidence). In all, there
ere 68 deaths during the 2,372 patient-years of follow-up
2.8% annual incidence). The estimated 1- and 2-year
urvival from this incidence is 97.2% and 94.4%, respec-
ively. A Kaplan-Meier survival plot is shown in Figure 2.
mong the 68 deaths reported, the most common causes—
ot unexpected in this population—were cardiovascular
ncluding MI and ventricular tachyarrhythmia. The most
ommon noncardiac causes of death were cancer and pul-
onary embolism (Table 6).
Table 7 compares the ROLE program mortality rates
ith those predicted by the DTS model and contemporary
reatment trials (6–12). Comparison cohorts were selected
n which patients had either refractory chronic angina or
oronary heart disease (CHD) with increased risk. With the
xception of the younger population reflected in the DTS
Figure 2 Survival Time During the ROLE Program and the
Original, Randomized Trials MARISA and CARISA
Kaplan-Meier estimate. Abbreviations as in Figure 1.
lectrocardiographic Findings ataseline and Average Values on Treatment
Table 5 Electrocardiographic Findings atBaseline and Average Values on Treatment
Interval
Number of
Patients
Assessed
Milliseconds (Mean  SE)
Baseline On Treatment
PR 739 167.1 1.0 167.2 0.9
QRS 745 94.6 0.5 93.5 0.4
QTc (Fridericia correction) 739 419.9 0.8 422.3 0.7aodel, comparative cohorts were of similar age as ROLE
rogram participants.
iscussion
he market availability of novel pharmaceutical products
nevitably generates both excitement and concern among
linicians. Although physicians might welcome ranolazine
s an agent that addresses the unmet need of treating CHD
ymptoms without altering hemodynamic status, safety
oncerns are understandable. These concerns are particu-
arly germane to cardiovascular therapeutics, recently in-
luding drugs such as flosequinone, mibefradil, and
esiritide—all agents that received regulatory approval on
he basis of symptom relief only to be subsequently with-
rawn or highly scrutinized after the release of safety data
hat were unavailable at the time of initial approvals.
Ranolazine was well tolerated during long-term treat-
ent, which is consistent with the findings of randomized,
ouble-blind studies (1,2,5). The most common side effects
ere dizziness and constipation, but these symptoms were
sually not severe enough to cause treatment discontinua-
ion. Overall, 76.7% of patients completed 2 years of
pen-label therapy. Of the 23.3% of patients who did not
omplete 2 years of therapy, less than one-half (9.7%)
topped study participation owing to AEs. Predictive mod-
ling showed a significantly increased likelihood of AE-
elated discontinuation associated with only 1 categorical
ariable, age64 years. Increased susceptibility to untoward
ffects with advancing age is common for many therapeutic
nterventions and is not an unexpected finding (13–15).
uriously, there was a decreased probability of AE-related
iscontinuation in patients with a history of CHF. Al-
hough this finding should be interpreted with caution, it is
ntriguing that improvements in ventricular function related
o ranolazine were observed in animal models (15,16).
The open-label methodology of the ROLE program does
ot allow for a rigorous analysis of mortality. Because of the
umulative Mortality to Date
Table 6 Cumulative Mortality to Date
Cause of Death Number of Deaths (%)
Any cause (total deaths) 68 (100.0)
CV deaths 54 (79.4)
Acute MI 23 (33.8)
MI, cardiogenic shock, acute coronary syndrome 3 (4.4)
Sudden death 15 (22.0)
Ventricular tachyarrhythmia 4 (5.9)
CHF, low-output syndrome, cardiac insufficiency 3 (4.4)
Cerebrovascular event 2 (2.9)
Pulmonary embolism 2 (2.9)
Cardiac arrest 1 (1.5)
Hemopericardium 1 (1.5)
Non-CV deaths (cancer, infection, respiratory failure,
bowel obstruction, accident, trauma unknown)
14 (20.6)
V  cardiovascular; other abbreviations as in Table 1.bsence of a comparator group, it is difficult to fully
Patient Survival in ROLE and Other Published Patient Cohorts
Table 7 Patient Survival in ROLE and Other Published Patient Cohorts
Publication Study Type Follow-Up Duration, yrs Study Population Age, yrs
Number of
Subjects Survival
Mark et al. (6,12) Historical observational 5 (median) Patients with heart catheterizations and
stress tests at Duke University Medical
Center Nov 1969–Jan 1981
49 (median) 2,842 (M: 70%) 4-yr rate by risk, Low (DTS 5): 99%;
Moderate (DTS 10 to 4): 95%;
High (DTS 10): 79%
Morrison et al. (8) Contemporary treatment
in high-risk population
3 16 VA centers enrolling patients with
medically refractory myocardial ischemia
undergoing high-risk CABG or PCI
Approx 40% of patients
70 yrs
760 3 yrs (reported by subsets) 65% to 86%
Allen et al. (9) Contemporary treatment
in high-risk population
1 Medically refractory class IV angina not
amenable to revascularization
TMR: 60  10
Med Rx: 60  11
(mean  SD)
TMR: 132
(M: 74%)
Med Rx: 143
(M: 76%)
1-yr TMR: 84%; Med Rx: 89%
Michaels et al. (7) Contemporary treatment
in high-risk population
2 Patients undergoing EECP for chronic angina 65.8  10.9
(mean  SD)
1,097 (M: 74%) 2 yrs 91.5%
Poole-Wilson et al. (11) Contemporary treatment
in lower-risk population
4.9  1.1 (mean  SD) Patients with stable angina. Abnormal
treadmill study not required.
Nifedipine: 63.5  9.3
Placebo: 63.4  9.3
(mean  SD)
Nifedipine: 3,825
(M: 80%)
Placebo: 3,840
(M: 79%)
Nifedipine GITS: 91.9%
Placebo: 92.4%
Pepine et al. (10) Contemporary treatment 2.7 (mean) Patients with CAD and hypertension 66  9.7 (mean  SD) 22,576 (M: 48%) CCB strategy: 92.2%
Non-CCB strategy: 92.1%
The ROLE program Current study 2.8 Patients with severe functional impairment
due to CAD who completed 1 of 2
randomized treadmill tests
63.6  9.0
(mean  SD)
746 (M: 78%) 2 yrs 94.4%
CABG  coronary artery bypass grafting; CAD  coronary artery disease; CCB  calcium channel blocker; DTS  Duke Treadmill Score; EECP  enhanced external counterpulsation; GITS  gastrointestinal therapeutic system; M  men; PCI  percutaneous coronary
intervention; TMR  transmyocardial revascularization; VA  Veterans Administration.
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March 13, 2007:1027–34 Safety of Long-Term Ranolazineharacterize implications of the 68 deaths reported. How-
ver, the mortality rate of 5.6% over 2 years can be placed into
ontext by comparing this result with predictions based on
TS and cohorts treated with other antianginal modalities.
High-risk DTS (10) has been associated with a
-year survival rate of 79%, intermediate-risk scores (10
o 4) with a 4-year survival risk of 75% to 95%, and
ow-risk scores (5) with a 4-year survival rate of 99%
6,12). The mean baseline DTS for ROLE patients, 14.4,
mplies a poor prognosis and a yearly mortality estimate above
%. The finding of an actual 2-year mortality of 5.6% and a
early mortality of approximately one-half the DTS predicted
ate is reassuring prognostic information about ranolazine.
lthough prognosis on the basis of the DTS might not reflect
ecent invasive and noninvasive advances in cardiovascular care
e.g., stents and statin use) and might overestimate contempo-
ary CHD mortality, the DTS cohort was significantly
ounger than ROLE program participants—an offsetting fac-
or that could lead to underestimation of DTS-predicted
ortality for the ROLE program patients.
Benchmarking outcomes in patients exposed to ranola-
ine with the prognosis reported in recent high-risk CHD
reatment trials is another useful comparison. In 1998, a
egistry was set up to assess treatment with enhanced
xternal counterpulsation (EECP) in patients with refrac-
ory angina (17). In 2001, Michaels et al. (7) described the
xperience of 978 patients at 43 centers, of whom 81% had
reviously undergone revascularization and 69% were con-
idered unsuited for either percutaneous coronary interven-
ion or coronary artery bypass graft surgery at the start of
reatment with EECP. Although EECP registry patients
ight have had more severe CHD, on average, in that they
ould be angina treatment failures despite multiple drugs,
hese patients might not be dissimilar prognostically to
OLE program participants who were required to have
ngina limiting exercise at low work levels ( end of Bruce
rotocol stage 1). Cumulative mortality among EECP
egistry patients was 8.5% at 2 years (7) versus 5.6% in
OLE program participants. Data from cohorts undergo-
ng other treatments for medically refractory angina such as
igh-risk coronary revascularization or surgical laser
ransmyocardial revascularization also show mortality rates
reater than the ROLE program cohort (8,9). By contrast,
tudies of lower-risk CHD populations have shown similar
10) or lower mortality risk (11).
The finding of mortality rates in the ROLE program at
r below expectations should help address concerns about
hether or not the QTc interval prolongation previously
eported in association with ranolazine use is of clinical
ignificance. Previous work with ranolazine demonstrated a
rolongation of the Bazett’s corrected QTc interval by 10
s (2). Although prolongation of QTc interval is associated
ith Torsades de Pointes, investigators (18) have shown
hat QTc interval prolongation alone is not sufficient to
ause Torsades de Pointes. Induction of early after depolar-
zations (EADs) and an increase in transmural dispersionre also required. Electrophysiologically, ranolazine does
ot induce EADs in animal models and reduces transmural
ispersion (19). In the ROLE program, there were no
nvestigator-ordered discontinuations related to QTc inter-
al prolongation or cases of Torsades de Pointes.
Although the safety results of the ROLE experience are
ncouraging, clinicians should maintain their vigilance for
ntoward effects. While the relatively large ROLE cohort
afety dataset should be predictive of patient experiences as
anolazine makes it way into routine clinical use, limitations
f the present study should be acknowledged. Some patients
n the original randomized studies terminated early from the
andomized studies because of AEs (7.9% of ranolazine
atients vs. 4.8% of placebo patients in the CARISA trial,
nd 1.1%, 0.6%, 0.6%, and 5.9% of patients treated with
lacebo, ranolazine 500 mg b.i.d., ranolazine 1,000 mg
.i.d., and ranolazine 1,500 mg b.i.d., respectively, in the
ARISA trial). Because completion of a blinded study was
equired to participate in the ROLE program we might
ave eliminated patients who were more intolerant of
anolazine and reduced the incidence of AEs in the ROLE
rogram. There was also no requirement for long-term
ystematic follow-up after patients discontinued medication
n the ROLE program. Although these discontinued pa-
ients are not expected to have any untoward long-term
omplications attributable to their use of the drug, this
ossibility cannot be entirely excluded.
onclusions
ong-term safety and tolerability of ranolazine in patients
ith chronic stable angina seems favorable without indica-
ion of increased long-term cardiac mortality compared with
eference populations. Electrophysiological complications
ere not a major determinant of study drug discontinuation.
anolazine discontinuation due to adverse experiences was
ore common in older patients. Because participation in
he ROLE program was voluntary, it is reasonable to
onclude that the high rate of patients continuing ranola-
ine open-label treatment reflects a perception of net benefit
or a symptomatic condition by study participants and their
hysicians.
eprint requests and correspondence: Dr. Michael J. Koren,
acksonville Center for Clinical Research, 4085 University Boule-
ard South, Suite 1, Jacksonville, Florida 32216. E-mail:
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